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Summary
Background Most hepatitis C virus (HCV) transmission in Egypt is related to medical injections and procedures. To 
control the spread of HCV, the Egyptian Ministry of Health initiated awareness and education campaigns, strengthened 
infection control in health-care facilities, and subsidised anti-HCV treatment. We aimed to investigate the eﬀ ect of 
these interventions on the spread of HCV by mathematical modelling.
Methods We developed a mathematical model of HCV transmission in Zawyat Razin, a typical rural community. Our 
model assumes that each individual has two distinct types of medical procedures: injections and more invasive 
medical procedures. To quantify the severity of the spread of HCV, we used the notion of the basic reproduction 
number R0, a standard threshold parameter signalling whether transmission of an infectious disease is self-sustained 
and maintains an epidemic. If R0 is greater than 1, HCV is self-sustained; if R0 is 1 or less, HCV transmission is not 
self-sustained. We investigated whether heterogeneity in the rate of injection or invasive medical procedures is the 
determinant factor for HCV transmission and whether most iatrogenic transmission is caused by a small group of 
individuals who receive health-care interventions frequently. We then assessed whether interventions targeted at this 
group could reduce the spread of HCV. 
Findings The R0 of the spread of HCV without treatment was 3·54 (95% CI 1·28–6·18), suggesting a self-sustained 
spread. Furthermore, the present national treatment programme only decreased R0 from 3·54 to 3·03 (95% CI 1·10–5·25). 
Individuals with high rates of medical injections seem to be responsible for the spread of HCV in Egypt; the R0 of the 
spread of HCV without treatment would be 0·64 (95% CI 0·41–0·93) if everybody followed the average behaviour. The 
eﬀ ect of treatment on HCV transmission is greatly enhanced if treatment is provided a mean of 2·5 years (95% CI 
0·1–9·2) after chronic infection and with drug regimens with more than 80% eﬃ  cacy. With these treatment parameters, 
preventive and curative interventions targeting individuals with high rates of medical injections might decrease R0 
below 1 for treatment coverage lower than 5%.
Interpretation Targeting preventive and curative interventions to individuals with high rates of medical injections in 
Egypt would result in a greater reduction the spread of HCV than would untargeted allocation. Such an approach 
might prove beneﬁ cial in other resource-limited countries with health-care-driven epidemics.
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Biology of Emerging Infectious Diseases.
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Introduction
Hepatitis C is a blood-borne disease that has been 
undergoing global spread for over 100 years.1 However, 
its causal agent, the hepatitis C virus (HCV), was 
identiﬁ ed only in 1989.2 Findings from epidemiological 
studies revealed large discrepancies in the spread of 
HCV around the world.3 In high-income countries, fewer 
than 2% of adults have anti-HCV antibodies.3 Because of 
routine HCV testing of blood products and increased use 
of disposable material and sterilisation measures in 
health-care facilities, HCV transmission is low in high-
income countries,4 remaining a major concern only for 
intra venous drug users.4–6
By contrast, HCV prevalence is in excess of 10% of the 
general adult population in some low-income and 
middle-income countries (eg, Egypt, Cameroon, and 
Mongolia).3 Medical procedures seem to be responsible 
for most HCV transmission in these countries.3 The 
2008 Egyptian Demographic and Health Survey7 
estimated that 15% of people aged 15–59 years in Egypt 
have anti-HCV antibodies and 10% (about 5 million) had 
chronic HCV infection. However, this high ﬁ gure is 
related to past transmission events and is not 
representative of the HCV transmission occurring in 
Egypt nowadays. The origin of this epidemic has been 
attributed to mass campaigns of parenteral 
antischistosomiasis treatment in the 1960s to 1980s, 
when intravenous injections with antimony salts were 
given to 3–5 million individuals older than 6 years.8 
Insuﬃ  cient sterilisation of medical equipment is 
regarded as the main cause of HCV transmission at that 
time.8 Since HCV-infected individuals can survive for 
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longer than 30 years, many people who were infected are 
still alive. They form an ageing cohort of HCV-infected 
individuals from whom HCV is still spreading to 
the general population through various health-care 
procedures (eg, injections, intravenous catheterisation, 
and surgery).9,10 Similar epidemiological situations have 
occurred in Cameroon and Gabon, where HCV might 
have spread greatly during past medical interventions 
(eg, anti-malaria treatment and transfusions).11,12
How much HCV is continuing to spread remains poorly 
understood; there are no reliable nationwide incidence 
estimates.13 Field studies have focused on identiﬁ cation of 
the medical procedures most responsible for HCV 
transmission.9,11 Still, whether this spread of HCV is 
self-sustained and what public health interventions can 
eﬃ  ciently reduce HCV transmission in the general 
population is not known.
To control the spread of HCV in Egypt, in 2008 the 
Ministry of Health launched an integrated national 
strategy,14 including awareness and education campaigns, 
strengthened infection control in health-care facilities, 
and subsidised anti-HCV treatment. The present public 
health strategy of Egypt is to make treatment available to 
everyone who attends one of 23 national treatment 
centres and fulﬁ ls the eligibility criteria. The treatment 
consists of a 48-week regimen with pegylated interferon 
alfa-2a and ribavirin and has a 60% probability of cure.15 
Limited resources prevent treatment of everybody in 
need: only 40 000 individuals can be treated per year, 
mostly around 15 years into their chronic phase, 
corresponding to F2 Metavir ﬁ brosis stage.16
To investigate the eﬀ ect of these interventions on 
HCV spread, we developed a mathematical model of 
HCV transmission using epidemiological data from a 
well-studied, typical rural community in Egypt.9 Since 
HCV transmission typically occurred during iatrogenic 
interventions,9 our model was speciﬁ cally designed to 
investigate how the frequencies at which individuals 
undergo medical procedures aﬀ ect the spread of HCV. 
Using our model, we investigated various hypothetical 
interventions, including early anti-HCV treatment—a 
strategy with recognised success against HIV 
transmission.17,18
Methods
Epidemiological data
We obtained data from two previous epidemiological 
studies in Zawyat Razin (appendix),9,19 a typical rural 
community in the Menoﬁ a Governorate with about 
20 000 inhabitants and a HCV antibody prevalence of 
11·8% in the 3–88 years age group, which is representative 
of the national level.9 We also included data from a 
2012 study (unpublished), in which we followed up 
individuals who, in 2002, reported frequent medical 
injections (appendix). We also included data from the 
2008 Egyptian Demographic and Health Survey.7
Mathematical model
We constructed a mathematical model describing HCV 
transmission in the general population of Zawyat Razin, 
calibrated to epidemiological data collected in Egypt. Our 
model was inspired by recent modelling work describing 
intravenous drug user communities.20 However, injecting 
drug use is extremely rare, if it happens at all, in the rural 
area of Zawyat Razin. Therefore, in view of the diﬀ erences 
in HCV epidemiology, we carefully reconsidered all 
modelling aspects (appendix).
Figure 1 shows the population ﬂ ow of the model. 
Susceptible individuals become acutely infected; at the 
end of the acute phase, they either spontaneously clear the 
virus or become chronically infected. Cured individuals 
can become reinfected and, at the end of a new acute 
phase, they either spontaneously clear the virus or became 
chronically infected. Chronically infected individuals can 
undergo treatment and recover, or else treatment is 
unsuccessful and they are no longer eligible for treatment.
In Egypt, HCV is typically transmitted through 
iatrogenic interventions in the general population,9 which 
makes the spread distinct in two regards. First, the 
population is heterogeneous with respect to their rates of 
injection and invasive medical procedures. Epidemio-
logical data show that 5% of the adult population takes 
more than 50% of all injections.7 Second, transmission of 
HCV occurs in health-care facilities—an environment 
where HCV prevalence is higher than in the general 
population.21
To accommodate these features of blood-borne trans-
mission, our model assumes that each individual has two 
distinct types of medical procedures: injections and more 
invasive medical procedures; the frequency at which an 
individual has these types of procedures is henceforth 
called the rate of access to health-care facilties. Further-
more, the rates of access to health-care facilities are not 
aﬀ ected by development of HCV disease—a reasonable 
assumption for HCV infection, which typically becomes 
symptomatic only in the late stages of chronic infection.22 
Figure 1: Flow diagram of the hepatitis C virus transmission model
The shaded box includes the transmission model in the absence of treatment. 
A=cured individual. C=chronically infected individual. F=treatment failure. 
I=acutely infected individuals. R=acutely reinfected individuals. S=susceptible 
individuals. T=treatment.
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Articles
www.thelancet.com/lancetgh   Vol 2   September 2014 e543
We stratiﬁ ed the populations in each stage of the ﬂ ow 
presented in ﬁ gure 1 over the rates of access to health-care 
facilities. This feature also allowed for a parsimonious 
modelling of the amount of infection in health-care 
facilities, which takes into consideration that the time 
scales of the clinical development of HCV infection are 
much longer than the duration of medical procedures 
(appendix).
Treatment response rates and other model parameters 
are according to genotype 4 HCV—the strain responsible 
for more than 90% of all infections in Egypt (appendix).23 
A decrease in unsafe iatrogenic procedures is modelled as 
a decrease in the probability of acquiring HCV per 
iatrogenic procedure after a HCV-infected patient has 
received treatment.
Calculation of the basic reproduction number R0
To quantify the severity of the spread of HCV, we used 
the notion of the basic reproduction number R0, a 
standard threshold parameter signalling whether the 
spread of HCV is self-sustained. R0 can be understood as 
the expected number of secondary infections caused by 
an infected individual in a disease-naive population 
during the individual’s infectious period. Therefore, R0 
does not depend on reinfection, which in the case of 
HCV remains poorly understood (appendix). Further-
more, if R0 is greater than 1, HCV spread is self-sustained; 
if R0 is 1 or less the self-sustained spread of HCV will 
stop. R0 is also widely used to quantify the eﬀ ect of a 
public health programme,18 although it does not specify 
when the public health programme will have the 
expected eﬀ ect.
The R0 of a compartmental model can be expressed as 
a function of the model parameters with the next 
generation methodology. Hence, the value of R0 and its 
corresponding 95% CI can be calculated with the 
parameter values and their uncertainties using the 
bootstrap method. In which suitable distributions are 
assigned to the parameters, these distributions are then 
sampled, and R0 is calculated for each parameter set to 
obtain a distribution of R0 that is used for summary 
statistics (appendix).
Modelling of whether transmission occurs through a 
core group
In a population with heterogeneous health-care practices, 
most iatrogenic transmission is possibly caused by a 
small core group of individuals who receive health-care 
interventions frequently. To test for this phenomenon, 
we modelled a homogeneous population in which 
everybody accesses health-care facilities at the mean 
rates. This scenario conserved the total number of 
iatrogenic exposures, changing only their distribution 
over the population.
R0 less than or equal to 1 for the model with a 
homogeneous population and R0 greater than 1 for the 
model with a heterogeneous population suggests that 
there exists a core group of individuals with frequent 
access to health-care facilities that maintains the spread of 
HCV, whereas most individuals remain exposed to HCV 
without transmitting the disease much. Further R0 
analyses can distinguish whether heterogeneity in the rate 
of injection or invasive medical procedures is the 
determinant factor (appendix).
Modelling the eﬀ ect of interventions when 
transmission is mediated by a core group
We distinguished two strategic dimensions to HCV 
prevention interventions when transmission is mostly 
caused by a core group: (1) targeting the core group with 
treatment and injection safety programmes, and (2) 
early testing and treatment (ie, the hit early, hit hard 
approach), initially proposed for the HIV epidemic.18 We 
designed a set of numerical experiments to investigate 
the multi faceted aspects of prevention of the spread of 
HCV. First, we compared targeted and untargeted 
injection manage ment alone. Second, we investigated 
targeted and untargeted strategies of treatment as 
prevention, contrasting treat early and treat late 
interventions by regimens with various eﬃ  cacies. 
Third, we explored combined strategies, including both 
injection manage ment and treatment, addressing both 
the core group and the general population. In the 
general Egyptian population, injection safety pro-
grammes might be as eﬃ  cient as those in other 
developing countries24,25 and maintaining the present 
levels of treatment seems feasible. We assumed that the 
individuals in the core group reached by the intervention 
programme stop 100% of their unsafe injection 
practices, but only 80% of this group could be treated 
because of existing comorbidities. We also assumed 
that the rest of the population achieves a 10% reduction 
in the number of unsafe injections and has a 10% 
chance of being treated if eligible.  
Assessment of the rate of leaving the core group
The success of a targeted public health intervention 
depends also on the rate of joining and leaving the core 
group—a feature not included in our mathematical model. 
If the rate is high, then in a short period of time a large 
number of individuals would be eligible for privileged 
interventions during the time they belong to the core 
group. Hence, in this case, the diﬀ erence between the 
targeted and untargeted strategies would not be signiﬁ cant. 
To address some of these concerns, we did a follow-up 
study in the Menoﬁ a cohort (unpublished). At baseline, in 
2002, we counted the number of individuals who self-
reported regular injection practices for various chronic 
medical disorders (eg, cardiovascular, metabolic, and 
rheumatic diseases). In 2012, we re-interviewed these 
individuals about their injection practices. We excluded 
self-injections of insulin from the count of injections since 
they were unlikely to contribute to HCV transmission to 
others (appendix).
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Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had the ﬁ nal 
responsibility for the decision to submit for publication.
Results
The R0 of our model without treatment was 
3·54 (95% CI 1·28–6·18). Hence, the spread of HCV 
would be self-sustained and persist even after the 
individuals infected during the antischistosomiasis 
campaigns died.
If everybody accessed health-care facilities at the mean 
rates calculated in the ﬁ eld studies7,9 (ie, 2·1 [95% CI 
0·0–20·0] injections and 0·23 [95% CI 0·00–1·61] invasive 
medical procedures per year; appendix), R0 would be 
0·64 (95% CI 0·41–0·93) in the absence of treatment—ie, 
the spread of HCV would decline without public health 
intervention if everybody followed the average behaviour. 
The mean rate of injections is nearly ten times larger 
than the mean number of invasive medical procedures. 
However, the probability of transmission by injection is 
nearly 20 times smaller than that by medical procedures 
(appendix). Further R analyses showed that an injection 
rate much higher than the mean is the key feature of 
individuals comprising the core group, whereas the rate 
of invasive medical procedures is not a major factor 
(appendix). Figure 2A shows that the core group is not 
delimited by a clear cutoﬀ  in the injection rate; rather, it 
occurs because a substantial fraction of the population 
takes injections at a rate much higher than the mean. 
This leaves arbitrariness in the deﬁ nition of the core 
group, which may be considered, for example, as the 5% 
of individuals with the highest rates of medical injections 
(more than ten per year) but also as the 2% of individuals 
with the highest rates of medical injections (more than 
24 per year).
Figure 3 presents modelling results for the decline in 
R0 caused by enhanced injection control programmes. 
R0 declines nearly linearly with non-targeted programme 
coverage and then approaches a plateau as almost all 
unsafe injections are eliminated. The R0 plateau remains 
slightly above 1, suggesting that injection control could 
almost eliminate the self-sustained spread of HCV in 
Egypt. However, a targeted approach might achieve a 
substantial decline in R0 with a much lower coverage; an 
example of such an approach might be prioritisation of 
patients with the highest injection rate for enrolment in 
the injection safety programme (ﬁ gure 3). In this case, 
R0 gets close to the plateau value when the top about 2% 
of people who receive injections most frequently 
completely give up their unsafe injection practices. We 
obtained similar results for less than perfect adherence 
(appendix).
For Zawyat Razin, our model predicted that the present 
national treatment strategy had only a slight eﬀ ect, 
decreasing R0 from 3·54 (95% CI 1·28–6·18) to 
3·03 (1·10–5·24), which suggests a self-sustained 
spread. Figure 4A shows that, at 60% eﬃ  cacy, the present 
national treatment strategy would not eliminate the 
Figure 2: Yearly rate of injections and invasive medical procedures in Egypt 
Yearly rate of (A) injections on the basis of Egyptian Demographic and Health 
Survey data7 covering the rural population and (B) invasive medical procedures 
on the basis of Zawyat Razin data.9
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Figure 3: The potential eﬀ ect of injection control on the severity of the spread of hepatitis C virus
The graph shows R0 (mean of bootstrap distributions) decline versus the coverage of the injection management 
programme after a non-targeted and targeted strategy. The black graph shows the result of including an increasing 
number of individuals under injection management, regardless of their health-care practices. The red graph shows 
the epidemiological eﬀ ect of injection management when enrolled individuals are prioritised by their injection 
rates. The inset displays a zoom-in of the main panel in the region of low coverage.
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spread of HCV even if everyone with HCV was treated 
within an average of 15 years of infection. Regimens at 
80% eﬃ  cacy would reduce the severity of the spread of 
HCV more but would still be deﬁ cient. Regimens at 
95% eﬃ  cacy would need to treat almost every infected 
individual to stop the self-sustained spread of HCV 
using the present national treatment strategy. However, 
our simulations suggest that early treatment would 
improve the outcome of mass-treatment interventions 
by reducing the duration of infectiousness of viraemic 
individuals. Figure 4B shows that, even for regimens 
with 60% eﬃ  cacy, a marked drop in R0 would occur if at 
least 20% of patients were treated a mean of 2·5 years 
(95% CI 0·1–9·2) after becoming chronically infected. 
Interventions with more eﬃ  cient regimens would not 
need to treat everybody with HCV to stop the self-
sustained spread of HCV. Figures 4C and D show the 
eﬀ ect of testing and treatment of the most frequent 
injectors on reducing the R0 of the spread of HCV. A 
marked drop in R0 could be obtained by treating fewer 
than 5% of the total eligible population.
We investigated the eﬀ ect of combining injection 
management and treatment, covering both the core 
group and the general population. Figure 5 shows colour 
maps of R0 versus the percentage participation of the core 
group and treatment eﬃ  cacy. We noted that targeting a 
restricted core group of 2% of the total population 
(ﬁ gure 5B) a mean of 15 years (95% CI 0·4–55·3) after 
infection would require high eﬃ  cacy regimens to 
decrease R0 below 1. However, targeting a broader core 
group of 5% of the total population with early treatment a 
mean of 2·5 years (95% CI 0·1–9·2) after infection shows 
that the self-sustained spread of HCV could be stopped, 
even if prevention programmes do not reach everybody in 
the core group (ﬁ gure 5C).
In our follow-up study in the Menoﬁ a cohort 
(unpublished), at baseline, in 2002, 82 (2%) of 
4020 individuals self-reported regular injection practices 
for various chronic medical disorders (appendix). The 
median age of these individuals was 32 years (IQR 15–45), 
with a male to female ratio of 0·86. 22 (27%) of 
82 individuals had HCV antibodies, corresponding to an 
age-standardised prevalence 1·64 (95% CI 1·03–2·48) 
times higher than that of the village cohort population. 
During cohort follow-up (2000–2012), regular injectors 
were more likely to be hospitalised (age-adjusted rate 
ratio 1·86, 95% CI 1·01–3·44) and to die (3·10, 1·87–4·85) 
than the rest of the village cohort population. In 2012, of 
the 60 individuals who did not die (n=13) or migrate out 
(n=7) or who were receiving regular insulin injections 
Figure 4: The eﬀ ect of various treatment strategies on the severity of the spread of hepatitis C virus
The graphs show R0 (mean of bootstrap distributions) versus the fraction of individuals treated after diagnosis according to various public health strategies. The results 
for making HCV treatment universally available a mean of (A) 15 years (95% CI 0·4–55·3) and (B) 2·5 years (0·1–9·2) after infection and for treating the core group of 
injectors, on average, (C) 15 and (D) 2·5 years after infection are shown. Since there is no deﬁ nite cutoﬀ  in the rate of injections that delimits the core group, the graphs 
show the eﬀ ect on R0 when the core group is gradually enlarged to include individuals with lower injection rates. HCV=hepatitis C virus.
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(n=2), 24 (40%) remained regular injectors—ie, receiving 
more than ten injections per year. Regular injectors 
reported receiving injections either at home (18 of 
19 [95%]) or in health-care facilities (nine of 19 [47%]) 
from medically trained (16 of 24 [67%]) or non-medically 
trained (13 of 24 [54%]) personnel. All regular injectors 
reported having intramuscular injections in the past 
6 months; ten (42%) of 24 reported having intravenous 
injections in the past 6 months.
Based on the follow-up survey, we estimated the mean 
yearly rate at which individuals quit taking frequent 
injections. We considered two distinct modelling cases to 
deal with the fact that 13 injectors died during the study. 
First, we assumed that all injectors had the same rate of 
quitting taking frequent injections, which was equal to 
the rate calculated for the injectors who were interviewed. 
Hence, we obtained a yearly rate of 8·4% (95% CI 
6·3–11·0), corresponding to a median time of 8 years 
(95% CI 6–11). Second, we assumed that all injectors who 
were still alive at the end of the study had the same rate of 
quitting taking frequent injections (equal to the rate 
calculated for the injectors who were interviewed), 
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Figure 5: The eﬀ ect of combined public health strategies targeting a core group on the severity of the spread of hepatitis C virus
Colour maps of R0 (mean of bootstrap distributions) versus treatment eﬃ  cacy and the fraction of a core group with frequent access to health-care facilities enrolled in 
the prevention programme are shown. White lines show the HCV spread threshold R0=1. Interventions with parameters above the white line would stop the self-
sustained spread of HCV, whereas interventions with parameters below the white line would just reduce the severity of the spread of HCV. Results are shown for 
treatment, on average, 15 years after infection of core groups representing (A) 5% and (B) 2% of the total population, and for treatment, on average, 2·5 years after 
infection of core groups representing (C) 5% and (D) 2% of the population. HCV=hepatitis C virus.
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whereas the injectors who died would have never quit 
taking frequent injections. In this case, we calculated a 
yearly rate of 6·5% (95% CI 4·7–8·7), corresponding to a 
median time of 10 years (95% CI 8–14).
Discussion
Mathematical models of HCV have been used to test 
prevention strategies and address topics relevant to high-
income countries where HCV transmission remains 
essentially conﬁ ned to intravenous drug users.20,26,27 These 
models cannot be used to describe generalised spread of 
HCV, such as in Egypt, because of stark diﬀ erences in 
HCV epidemiology. Indeed, HCV transmission pathways 
are diﬀ erent in the two cases: social networks mediate 
HCV transmission in intravenous drug users, whereas 
for the spread of HCV in the general population of Egypt, 
injection providers play the key part. Furthermore, 
annual HCV incidence in intravenous drug users ranges 
from 6% to 40%,28 about 100 times higher than estimated 
incidence in rural communities of Egypt (0·08–0·68%).13,19
Here, we have described the ﬁ rst mathematical model 
of HCV transmission in a high-prevalence setting and 
calculated the basic reproduction number R0 using 
epidemiological data (panel). Our model suggests that, 
without treatment interventions, HCV transmission 
would be self-sustained in Egyptian rural communities, 
maintaining a nationwide spread of HCV. Furthermore, 
present public health measures including increased 
access to treatment would not reduce substantially the 
severity of the spread and would need a large coverage for 
an eﬀ ect on the spread of HCV.
Real-world HCV prevention strategies will probably be 
complex, combining targeted and untargeted inter-
ventions, injection control, and treatment. Individuals 
with high injection rates (ie, more than ten injections per 
year, representing <5% of the population) perpetuate 
HCV transmission in Egypt, whereas the rest of 
individuals remain exposed without transmitting the 
disease much. Individuals undergoing frequent medical 
procedures are more likely to become infected early, and, 
by continuing their practice, transmit HCV to others. In a 
ﬁ eld study (unpublished), the core group of HCV 
transmitters consisted mainly of individuals with chronic 
medical disorders who maintained their injection 
practices for 8–10 years. Hence, interventions targeting 
this core group would be beneﬁ cial public health 
strategies and would have nearly the same eﬀ ect in 
reducing transmission as untargeted programmes with 
much larger coverage.
Core groups consisting of sex workers (for HIV) or 
illicit drug users (for both HIV and HCV) are often 
diﬃ  cult to reach because of stigma or the illegal nature of 
their activities. However, in this case, core group members 
could be reached easily since they self-identify by 
accessing health-care facilities to receive care and 
management. The intervention should therefore consist 
of raising awareness of health-care providers to HCV 
testing of individuals with chronic disorders who need 
frequent medical procedures. If patients are HCV-
antibody negative (or HCV-antibody positive but RNA 
negative), they should be counselled on safe injection 
procedures and reduction of unnecessary injections. 
Patient education will therefore be crucial to the success 
of this preventive intervention. Findings from our survey 
and those of others29 on injection practices in Egypt have 
shown that non-medically trained personnel have a major 
role in delivering injections. The importance of using 
disposable injection material should be particularly 
stressed, both to patients and injection providers.
If individuals are HCV RNA positive, they should be 
treated as a priority, eventually beneﬁ ting from next-
generation antiviral treatments with improved eﬃ  cacy, 
tolerance, and compatibility with possible comorbidities.30 
We showed that early intervention (~2·5 years after 
Panel: Research in context
Systematic review
With the advent of highly eﬀ ective antiviral therapy for chronic 
hepatitis C, the strategies to reduce the spread of the hepatitis C 
virus (HCV) might  become more diverse. When a similar 
situation occurred for the HIV epidemic, ﬁ ndings from 
modelling18 and subsequent ﬁ eld studies17 showed outstanding 
potential for new prevention strategies to reduce HIV spread in 
low-income and middle-income countries. We did a PubMed 
search of titles and abstracts on Dec 5, 2013, with the terms 
“HCV”, “transmission”, “antiviral”, “treatment” and “model*”, 
which identiﬁ ed 12 reports. Four reports described virus–host 
interactions and eight reports addressed the eﬀ ect of hepatitis C 
treatment on HCV spread among injecting drug users. We did 
not ﬁ nd studies on people who were not injecting drug users in 
low-income and middle-income countries—by far the largest 
HCV infected population worldwide. Therefore, we designed a 
mathematical modelling study using ﬁ eld data from Egypt—a 
country with very high HCV prevalence. We used our model to 
assess the eﬀ ect on HCV spread of several public health 
interventions that combine reductions in unsafe injections with 
treatment of infected individuals.
Interpretation 
Our model identiﬁ ed individuals with high rates of medical 
injections (more than ten per year), representing 5% of the 
entire population, and receiving more than 50% of all 
injections, as responsible for the spread of HCV in Egypt. 
Targeting these individuals with preventive or curative 
interventions would have a much greater eﬀ ect on HCV spread 
than would untargeted interventions—a key parameter to 
maximise is the eligibility of these individuals to undergo HCV 
treatment. The eﬀ ect of hepatitis C treatment on HCV 
transmission will be much greater if treatment is given early in 
the course of the infection (eg, 2·5 years after infection) and 
drug regimens with more than 80% eﬃ  cacy are used. Such an 
approach might prove beneﬁ cial in other resource-limited 
settings with health-care-driven epidemics.
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infection) in this core group was more beneﬁ cial than late 
intervention (~15 years after infection). However, more 
eﬀ ort in the initial phase of implementation would be 
needed for early treatment since about 90% of infected 
individuals would qualify for treatment, com pared with 
about 50% in the case of the late treatment strategy. 
Nevertheless, in the long run, such an endeavour would 
prove fruitful since HCV-infected individuals would get 
earlier access to treatment and thus the risk of disease 
transmission would be reduced. We also showed that 
treatment for prevention has greater eﬀ ect with regimens 
of eﬃ  cacy higher than 80%, administered early in the 
course of infection. To implement treatment for 
prevention would require frequent HCV testing—quite 
feasible for this population with high rates of medical 
injections and thus frequent access to health-care facilities.
The main limitation of our approach is that it relies 
exclusively on the notion of R0. Although R0 is crucial  for 
identiﬁ cation of eﬀ ective public health strategies,18,31 it 
does not provide a complete epidemiological description. 
Reduction in R0 does not translate into easy-to-read 
indicators for policy makers (eg, HCV prevalence decline 
or calendar years left until meeting expected eﬀ ect of 
interventions). Also, R0 is independent of HCV 
reinfection; hence the eﬀ ect of reinfection on the eﬃ  cacy 
of interventions cannot be revealed by R0 analyses. 
However, in a recent meta-analysis,32 Aspinall and 
colleagues argue that the incidence of reinfection is 
probably low in intravenous drug users, with an 
estimated pooled risk of reinfection of 2·4 per 100 person-
years. The reinfection risk is probably negligible in the 
general population of Egypt, where HCV incidence is 
much lower than that in intravenous drug users.
After the 2010 hepatitis resolution,33 WHO released 
guidelines for viral hepatitis control.34 An issue that 
remains crucial for HCV global health policy is the price 
at which next-generation antiviral treatment regimens 
will be made available to low-income and middle-income 
countries. In Egypt, pharmaceutical companies have 
already started testing some of the new direct antiviral 
drugs (NCT01838590); price negotiations with the 
government will follow, provided trial results show high 
eﬃ  cacy. Gilead recently concluded an agreement with the 
Egyptian Government to provide sofosbuvir at US$900 
for 12 weeks of treatment.35 The price is low compared 
with that oﬀ ered in the USA ($84 000),35 but is still high 
for individual patients or government subsidies in low-
income or middle-income countries. If, in such settings, 
HCV is transmitted mostly iatrogenically, then we 
propose prioritising treatment for patients with advanced 
disease or who belong to the core group to reduce 
substantially both HCV mortality and transmission. 
However, treatment interventions should not overshadow 
improvements in injection management and infection 
control, which are likely to be more cost-eﬀ ective and 
might also reduce the transmission of other blood-borne 
pathogens such as HIV and hepatitis B virus.
In conclusion, by developing a mathematical model 
tailored to a typical rural community in Egypt, we have 
identiﬁ ed fundamental aspects of HCV transmission 
and control that might apply to other areas of high HCV 
prevalence. Oﬀ ering HCV treatment and counselling on 
injection use to patients with chronic HCV who receive 
regular health-care interventions seems to be eﬀ ective in 
reducing HCV transmission and is timely and feasible 
in view of the economic constraints of Egypt.
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